drugset / Trial / NCT00612664
Phase II, 2nd Line Melanoma - RAND Monotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks
Timeline
- Start
- 2008-03
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Urelumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Comparator | Urelumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Comparator | Urelumab | Monoclonal antibody | 5 mg/kg | Intravenous |